Other Stories

Oxford's COVID-19 vaccine shows promising immune response in human trials Updated: 2020-07-21 17:07:07 KST

A potential COVID-19 vaccine developed by Oxford University has reportedly produced a promising immune response in a large, early-stage human trial.
According to data published Monday in the medical journal, The Lancet, 100 percent of some 1-thousand participants in the trial developed antibodies.
Jointly developed with pharmaceutical giant AstraZeneca, the vaccine also produced killer T-cells that help patients combat the infection by attacking the infected cells.

"What we now need to find out is whether the group who have the coronavirus vaccine are protected and they don't get disease, and that needs time for those cases to accumulate within the clinical trial to give us confidence, statistically speaking, about whether the vaccine works."

Other vaccine developers also had positive news, with America's Pfizer and Germany's BioNTech successfully immunizing their 60 participants.
Pfizer and BioNTech now plan to begin testing on some 30-thousand volunteers this month to prove the efficacy of their vaccine.
Human trials on treatments for the virus are also accelerating.
The effects of treatments like Remdesivir and hydroxychloroquine remain uncertain and are only reported to work on limited groups, but a convalescent plasma therapeutic which uses COVID-19 antibodies extracted from recovered patients is on the rise as an alternative.
A website by the U.S. National Institutes of Health that tracks clinical trials in action shows the number of clinical trials for a plasma treatment increased to around 120 in July.
That's up from just 3 trials in March.
But while its considered one of the most practical treatments for the virus,ramping up collection of the plasma is proving a challenge.
Choi Jeong-yoon, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.